Search results
Download Complete Annual Report. Managing Director’s Message and Management Discussion & Analysis. Board’s Report and Corporate Governance. Business Responsibility and Sustainability Report. Standalone Financial Results. Consolidated Financial Results.
Sun Pharmaceutical Industries Limited | Annual Report 01-22 We continue to focus on improving the efficiency and productivity of our R&D operations, targeted at faster
Sun Pharmaceutical Industries Limited ANNUAL REPORT 2022-23 Reaching People. Touching Lives.
Sun Pharma is ranked No. 1 and holds 8.3% market share in the over Rs. 1,688 Billion Indian pharmaceutical market as per AIOCD AWACS MAT March-2022 report. For Q4FY22, the company launched 11 new products in the Indian market. US Formulations (including Taro)
Sun Pharma holds 8.3% market share and is ranked No. 1 in the Rs. 1,850 Billion plus Indian pharmaceutical market as per AIOCD AWACS MAT March-2023 report. For Q4FY23, the company launched 24 new products in the
Investor Presentation – January 2024. At Sun, we remain committed to creating long term value for our shareholders. In line with this philosophy, we will continue to focus on performance and producing consistent returns.
Sun Pharma is ranked No. 1 and holds 8.2% market share in the over Rs. 1,671 Billion Indian pharmaceutical market as per AIOCD AWACS MAT December-2021 report. For Q3FY22, the company launched 25 new products in
submitting herewith the Annual Report including the Business Responsibility Report of the Company for the financial year 2020-21 alongwith the Notice of the 29th Annual General Meeting of the Company, scheduled to be held on Tuesday, August 31, 2021 at 03.00 p.m.
Sun Pharmaceutical Industries Ltd. Annual Reports: Review of financial performance, strategy, and achievements.
Get a detailed Sensex annual report of Sun Pharmaceutical Industries on stock/share exchange market for the financial 2021 and more at Moneycontrol.com.
